Mangoceuticals' MangoRx IP sells 25% stake for $2.5M; $1.75M received, no MGRX shares issued

MANGOCEUTICALS, INC.

Two accredited investors agreed to buy an aggregate 25% membership interest in subsidiary MangoRx IP Holdings for $2.5M; $1.75M (17.5% post-transaction) already received.
First investor paid $500,000 upfront in cash or Tether (USDT) plus $750,000 within 60 days; remaining 7.5% costs $750,000, due by November 28, 2026.
No MGRX common stock, warrants or other parent securities issued; CEO Jacob Cohen says the deal preserves the public capitalization structure.
MangoRx IP owns the MGX-0024 antiviral portfolio, led by U.S. Patent No. 11,517,523, with granted or pending patents in the EU, Canada, China, India, Australia and Japan.
Company cites Fortune Business Insights 2025 markets of ~$34.8B for global oral care and ~$39.8B for feed additives as potential applications.

item 1.01 item 2.01 item 9.01 item 3.02 item 7.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.